Hawaii 2026 Regular Session

Hawaii House Bill HB2321

Introduced
1/28/26  
Refer
2/2/26  
Refer
2/13/26  
Report Pass
3/5/26  
Engrossed
3/10/26  

Caption

Relating To The Uniform Controlled Substances Act.

Impact

The bill is anticipated to strengthen the state's ability to combat drug abuse by ensuring that any new substances that may emerge in response to existing controls can be swiftly categorized and regulated. This proactive approach is crucial in the face of the ongoing opioid crisis and the emergence of synthetic drugs that pose significant public health risks. By aligning state law with federal definitions and schedules, the bill aims to expand the tools available to law enforcement and public health officials for addressing substance misuse and trafficking effectively.

Summary

House Bill 2321 (HB2321) relates to the Uniform Controlled Substances Act in Hawaii. Its primary aim is to amend Section 329-14 of the Hawaii Revised Statutes to ensure that the state law aligns with updates and amendments made to the federal Controlled Substances Act. This alignment process is important as it allows for more uniform regulation of substances known to have potential abuse and addiction issues, particularly concerning opioids and other narcotic drugs. The bill proposes specific changes to the definitions of certain substances, effectively adding new drugs to the controlled substances list, including various potent opioids and analogs.

Sentiment

The sentiment surrounding HB2321 appears generally supportive among legislators and advocacy groups concerned with public health and safety. Many express a strong desire to see stringent measures against the burgeoning opioid crisis and the potential dangers posed by unregulated substances. However, concerns regarding civil liberties and the potential for overreach in drug scheduling also exist, indicating a nuanced debate around the balance between regulation and personal freedom.

Contention

Despite the overall support for the bill, some points of contention have emerged, particularly regarding the potential implications for individuals who may be prescribed medications that fall under these classifications. Concerns about adequate access to pain management medications and the fear of excessive regulation leading to unintended consequences are notable. Additionally, the bill's effectiveness will likely hinge on ongoing discussions about public health strategies and resource allocation for treatment and prevention initiatives related to substance misuse.

Companion Bills

HI SB3141

Same As Relating To The Uniform Controlled Substances Act.

Previously Filed As

HI SB1452

Relating To The Uniform Controlled Substance Act.

HI HB1133

Relating To The Uniform Controlled Substance Act.

HI HB1482

Related To Controlled Substances.

HI HB917

Relating To Sentencing.

HI SB279

Relating To Dangerous Drugs.

HI HB386

Relating To Dangerous Drugs.

HI HB1184

Relating To Controlled-environment Agriculture.

HI SB1158

Relating To Controlled-environment Agriculture.

HI SB738

Relating To Wastewater Management.

HI SB683

Relating To Environmental Protection.

Similar Bills

HI SB3141

Relating To The Uniform Controlled Substances Act.

ND HB1101

The scheduling of mitragynine as a schedule I controlled substance.

HI SB1452

Relating To The Uniform Controlled Substance Act.

MS SB2117

Uniform Controlled Substances Act; revise Schedule I.

MS HB417

Uniform Controlled Substances Act; include five substances in Schedule I.

MS SB2356

Uniform Controlled Substances Act; revise Schedule I.

MS HB1608

Uniform Controlled Substances Act; include 16 substances in Schedule I.

MS HB864

Kratom; add to Schedule I of the Uniform Controlled Substances Act.